VfendaFC Tablets & Powder For Solution For Infusion
PDF Leaflet Revision Date: 18 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of invasive aspergillosis and serious Candida infections.
Dosage (summary)
Loading dose: 6 mg/kg IV or 400 mg oral every 12 hours for 24 hours; Maintenance: 3-4 mg/kg IV or 200 mg oral every 12 hours.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding not recommended during treatment.
Key Drug Interactions
- CYP3A4 substrates
- Phenytoin
- Efavirenz
- Rifampicin
- Carbamazepine
Contraindications
- Hypersensitivity to voriconazole
- Severe hepatic impairment
- Co-administration with certain CYP3A4 substrates
Common side effects
- Visual disturbances
- Nausea
- Vomiting
- Rash
- Headache
Counselling Points
- Avoid sun exposure
- Monitor for visual changes
- Report any skin reactions
- Ensure electrolyte levels are normal before starting therapy
Serious warnings
- QTc prolongation
- Hepatic toxicity
- Severe cutaneous adverse reactions
Important Disclaimer
The VfendaFC Tablets & Powder For Solution For Infusion professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
